Table of Content

1. Product Overview
2. Research Methodology
3. Executive Summary
4. Voice of Customer
4.1. Brand Awareness
4.2. Factors Influencing Purchase Decision
4.3. Unmet Needs & Challenges
5. Global Biosimilar Insulin Market Overview
6. Europe Biosimilar Insulin Glargine & Lispro Market Outlook
6.1. Market Size & Forecast, (2014-2024)
6.1.1. By Value (USD Million) & Volume (Million Units)
6.2. Market Share & Forecast (2014-2024)
6.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.2.2. By Country (United Kingdom, Germany, France, Spain, Italy, Russia, Netherlands, Poland, Turkey & Rest of Europe)
6.2.3. By Company (2018)
6.3. Market Attractiveness Index
6.4. Competition Outlook
6.4.1. Major Biosimilar Insulin Glargine & Lispro Suppliers with products registered and sold
6.5. Country Analysis
6.5.1. Germany Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.1.1. Market Size & Forecast
6.5.1.1.1. By Value & Volume
6.5.1.2. Market Share & Forecast
6.5.1.2.1. By End User
6.5.2. United Kingdom Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.2.1. Market Size & Forecast
6.5.2.1.1. By Value & Volume
6.5.2.2. Market Share & Forecast
6.5.2.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.3. France Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.3.1. Market Size & Forecast
6.5.3.1.1. By Value & Volume
6.5.3.2. Market Share & Forecast
6.5.3.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.4. Italy Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.4.1. Market Size & Forecast
6.5.4.1.1. By Value & Volume
6.5.4.2. Market Share & Forecast
6.5.4.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.5. Spain Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.5.1. Market Size & Forecast
6.5.5.1.1. By Value & Volume
6.5.5.2. Market Share & Forecast
6.5.5.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.6. Russia Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.6.1. Market Size & Forecast
6.5.6.1.1. By Value & Volume
6.5.6.2. Market Share & Forecast
6.5.6.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.7. Turkey Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.7.1. Market Size & Forecast
6.5.7.1.1. By Value & Volume
6.5.7.2. Market Share & Forecast
6.5.7.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.8. Poland Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.8.1. Market Size & Forecast
6.5.8.1.1. By Value & Volume
6.5.8.2. Market Share & Forecast
6.5.8.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.9. The Netherlands Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.9.1. Market Size & Forecast
6.5.9.1.1. By Value & Volume
6.5.9.2. Market Share & Forecast
6.5.9.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
6.5.10. Austria Biosimilar Insulin Glargine & Lispro Market Outlook
6.5.10.1. Market Size & Forecast
6.5.10.1.1. By Value & Volume
6.5.10.2. Market Share & Forecast
6.5.10.2.1. By End User (Type 1 Diabetes, Type 2 Diabetes)
7. Market Dynamics
7.1. Drivers
7.2. Challenges
8. Market Trends & Developments
9. Porter’s Five Forces Analysis
9.1. Bargaining Power of Suppliers
9.2. Bargaining Power of Consumers
9.3. Threat of New Suppliers
9.4. Threat of Substitute
9.5. Competitive Rivalry
10. Competitive Landscape
10.1. Competition Outlook
10.2. Company Profiles
10.2.1. Basic Financial Details (Revenue, Gross Profit, Net Profit)
10.2.2. Sales Value and Volume of Product of Interest
10.2.3. Key Strategies
10.2.3.1. New Products Launches
10.2.3.2. Product Development Plan
10.2.3.3. Expansion Plan
10.2.4. Supply Chain Analysis
10.2.5. Business Distribution
10.2.6. SWOT Analysis
11. Timelines from Drug Development to Commercial Launch
12. Strategic Recommendations



List of Figures


Figure 1: Europe Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F (USD Million)
Figure 2: Europe Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 4: Europe Diabetic Population Share, 2017
Figure 3: Germany Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 4: Germany Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 5: United Kingdom Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 6: United Kingdom Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 7: France Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 8: France Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 9: Italy Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 10: Italy Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 11: Spain Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 12: Spain Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 13: Russia Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 14: Russia Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 15: Turkey Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 16: Turkey Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 17: Poland Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 18: Poland Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 19: The Netherlands Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 20: The Netherlands Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 21: Austria Biosimilar Insulin Glargine and Lispro Market Size, By Value and By Volume, 2014-2024F
Figure 22: Austria Biosimilar Insulin Glargine and Lispro Market Share, By End-User, 2014-2024F
Figure 23: Europe Biosimilar Insulin Glargine and Lispro Pricing Analysis, 2014-2024F